Status:
UNKNOWN
Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Chronic Hepatitis C Virus Infection
Eligibility:
All Genders
18+ years
Brief Summary
A relatively large proportion of patients with chronic HCV infection have normal or mildly elevated ALT. Many of these patients are not being treated, and are not being sent for a liver biopsy. The pr...
Detailed Description
The rational for using MBIT in the management of HCV in patients with persistently normal (and slightly elevated) ALT: * If MBIT is impaired, this indicates fibrosis \>2: a trigger to begin treatment...
Eligibility Criteria
Inclusion
- Men or women\>18
- Patients with HCV RNA+ above 105 copies Patients with normal liver enzymes on two tests 3 months apart, or up to \<X1.5 of upper normal
- Patients with biopsy proven HCV or (9 months prior to test with no anticipated changes in liver disease since biopsy).
Exclusion
- Other liver disorders.
- Active infections.
- Use of drugs that are known to induce/suppress P4501A2
- Pulmonary diseases
- Consumption of \>20cc alcohol a day prior to the test.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00294489
Start Date
February 1 2006
End Date
December 1 2006
Last Update
February 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120